Press Releases

Date Headline
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Results presented   today   at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 12.5 months Ongoing Phase 3 randomized clinical trial,  Continue Reading
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
Provides updated key priorities and focus on enterprise value framework Closing of Jazz Pharmaceuticals (Jazz) collaboration in fourth quarter completes financial transformation initiatives originally planned for 2022 Announces additional financial guidance on expected cash runway; provides  Continue Reading
Displaying 21 - 22 of 22